BML-278

BML-278 is a SIRT1 activator (EC150: 1 μM) . BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in both the paternal and maternal pronucleus. BML-278 improves early embryonic development. BML-278 arrests the cell cycle at the G1/S phase, and reduces senescence in primary human mesenchymal cells. BML-278 reduces tubulin acetylation in U937 cells. BML-278 also increases mitochondrial density in murine C2C12 myoblasts[1][2].

Product Specifications

CAS Number

[120533-76-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Histone Methyltransferase; Sirtuin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bml-278.html

Concentration

10mM

Purity

98.49

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CCOC(C1=CN(C=C(C(OCC)=O)C1C2=CC=CC=C2)CC3=CC=CC=C3)=O

Molecular Formula

C24H25NO4

Molecular Weight

391.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Adamkova K, et al. SIRT1-dependent modulation of methylation and acetylation of histone H3 on lysine 9 (H3K9) in the zygotic pronuclei improves porcine embryo development. J Anim Sci Biotechnol. 2017 Nov 1;8:83.|[2]Mai A, et al. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem. 2009 Sep 10;52 (17) :5496-504.